You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.



Kedrion Biopharma runner up at the Premio Equita for the bond issued in July 2017

The prize is awarded to the companies that made the best use of the capital markets

read more 


Kedrion Biopharma joins Columbia University to celebrate 50 years of Anti-D

Since 1968, billions of babies have been saved from Hemolytic Disease of the Fetus and Newborn

read more 


Hemophilia: Kedrion signs on to groundbreaking PARTNERS programme

Goal is to improve access to replacement therapies for coagulation disorders in Europe

read more 
  1. EVENTS - 17-04-2016

    Kedrion initiatives for World Hemophilia Day 2016

    The goal is to improve access to treatments for people suffering from hemorrhagic conditions

    read more 
  2. CORPORATE - 07-03-2016

    CURhE, Global Alliance for mother and child healthcare

    Kedrion among the founding members. The aim is Rh disease eradication

    read more 
  3. CORPORATE - 19-01-2016

    Kedrion Biopharma strengthens its position on the US market

    Granted exclusive rights to commercialize a lifesaving drug in the US

    read more 
  4. CORPORATE - 18-01-2016

    A brand new location for KEDPlasma donors in the very center of Fürth

    Plasma collected is turned into life-saving therapies to serve patients in Germany and worldwide

    read more 


For more information please contact: